CDSCO clears recombinant live attenuated dengue vaccine for ages 4 to 60 years
The Central Drugs Standard Control Organisation (CDSCO) granted marketing authorisation to a recombinant, live-attenuated tetravalent dengue vaccine for use in individuals aged 4 to 60 years, marking the first dengue vaccine approved for use in India.
The approval followed a comprehensive scientific evaluation of the vaccine's quality, safety and efficacy, as stated by the Union Ministry of Health and Family Welfare.
The evaluation drew on a pivotal Phase III safety and immunogenicity study conducted specifically in the Indian population across the approved age band.
Unlike an earlier dengue vaccine candidate that required pre-vaccination screening for prior dengue exposure, this vaccine's approval does not mandate serostatus testing before administration.
CDSCO Regulatory Approval Process — New Drugs and Clinical Trials Rules, 2019
The Central Drugs Standard Control Organisation, functioning under the Directorate General of Health Services, Ministry of Health and Family Welfare, is India's National Regulatory Authority for drugs and vaccines. Vaccine approvals in India are governed by the New Drugs and Clinical Trials Rules, 2019 (NDCT Rules), which superseded the earlier Schedule Y framework under the Drugs and Cosmetics Rules, 1945.
Key Details
- Under the NDCT Rules, 2019, all vaccines are classified as "new drugs" by default (Rule 2), regardless of how long they have been marketed elsewhere, unless the Licensing Authority certifies otherwise.
- For vaccines developed outside India, the Central Licensing Authority (CDSCO) can require repeat Phase I trials or permit concurrent Phase II/III trials alongside global trials, and typically mandates an India-specific bridging or pivotal study before approval — consistent with the Phase III study conducted in the Indian population for this vaccine.
- Clinical trial applications are required to be processed by the Central Licensing Authority within 90 working days of receipt under the NDCT Rules.
- Vaccine approvals also involve review by CDSCO's Subject Expert Committees (SECs), which assess trial data before a recommendation for marketing authorisation is made.
The dengue vaccine's approval process — including an India-specific pivotal Phase III trial — illustrates how the NDCT Rules, 2019 require localised safety and immunogenicity evidence even for vaccines already approved and used internationally.
Dengue as a Notified Vector-Borne Disease — NVBDCP Framework
Dengue is one of the vector-borne diseases addressed under India's National Vector Borne Disease Control Programme (NVBDCP), launched in 2003-04 to integrate control strategies for malaria, filariasis, dengue, Japanese encephalitis, kala-azar and chikungunya. Dengue is caused by four antigenically related but distinct serotypes (DENV-1 to DENV-4) transmitted primarily by the Aedes aegypti mosquito, a day-biting species that breeds in stagnant, man-made water containers in urban areas.
Key Details
- Because dengue has four serotypes, infection with one serotype does not confer immunity against the others; a subsequent infection with a different serotype carries a higher risk of severe dengue (dengue haemorrhagic fever/dengue shock syndrome) due to antibody-dependent enhancement.
- NVBDCP's dengue control strategy relies on integrated vector management (source reduction, larvicides, larvivorous fish) and disease surveillance rather than vaccination, since until this approval no dengue vaccine was licensed for use in India.
- A tetravalent vaccine (protecting against all four serotypes) is considered essential for dengue, unlike single-serotype approaches, because partial protection can theoretically increase severe-disease risk upon exposure to an unprotected serotype.
The newly approved vaccine is tetravalent, targeting all four DENV serotypes, and its introduction adds a vaccination pillar to NVBDCP's existing vector-management-based dengue control strategy for the first time in India.
Comparative Vaccine Case Study — Dengvaxia and the Seronegative Risk Controversy
Dengvaxia, developed by Sanofi Pasteur, was the world's first licensed dengue vaccine (2015) but became a cautionary case study in vaccine regulation after post-marketing data showed it increased the risk of severe dengue in individuals who had never previously been infected (seronegative recipients). Following a mass vaccination controversy in the Philippines (2016-17) involving over 830,000 children vaccinated without prior serological screening, the WHO in 2017-18 restricted Dengvaxia's recommended use to individuals with confirmed prior dengue infection (a "screen-and-vaccinate" approach, ages 9-45).
Key Details
- The Dengvaxia episode is a standard case study in vaccine pharmacovigilance and post-marketing surveillance, illustrating why regulators increasingly require serostatus-independent safety data for dengue vaccine candidates.
- The newly approved vaccine's approval — without a serostatus screening requirement — reflects a different underlying immunological design (a DENV-2 backbone with all four serotype antigens) and Phase III data supporting safety regardless of prior dengue exposure status.
- The vaccine has been administered in over 24 million doses across more than 40 countries and has received WHO prequalification, indicating it meets international quality, safety and efficacy benchmarks.
India's approval, without a screening prerequisite, positions this as a materially different regulatory and public-health proposition compared to the Dengvaxia precedent, reducing implementation complexity for any future large-scale immunisation rollout.
- Approved age group: 4 to 60 years
- Vaccine type: recombinant, live-attenuated, tetravalent (protects against DENV-1 to DENV-4)
- Dosing schedule: two 0.5 ml doses, administered three months apart (subcutaneous)
- Regulatory basis: New Drugs and Clinical Trials Rules, 2019, administered by CDSCO under the Ministry of Health and Family Welfare
- Global regulatory status: approved in more than 40 countries including the EU, UK and Switzerland; WHO-prequalified
- Doses administered globally: over 24 million
- NVBDCP launch year: 2003-04
- Primary vector: Aedes aegypti (day-biting, breeds in man-made water containers)
- Comparator vaccine: Dengvaxia (Sanofi, 2015) — restricted by WHO in 2017-18 to seropositive individuals aged 9-45 after severe-dengue risk was found in seronegative recipients